🇺🇸 FDA
Patent

US 8709995

Method for eliciting an immune response to human telomerase reverse transcriptase

granted A61KA61K2039/55505A61K2039/55511

Quick answer

US patent 8709995 (Method for eliciting an immune response to human telomerase reverse transcriptase) held by The Regents of the University of Colorado expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/55505, A61K2039/55511, A61K2039/55516, A61K2039/55544